Objective: This paper demonstrated the effectiveness of intrastromal injection of levofloxacin 1.5% ophthalmic solution in the management of recalcitrant Gram-positive bacterial keratitis. Methods: This is a report on two cases of recalcitrant bacterial keratitis encountered at the External Diseases and Cornea Clinic of the Department of Ophthalmology and Visual Sciences at the Philippine General Hospital. Results: Two middle-aged females presented with bacterial keratitis unresponsive to previous antibiotic treatment with impending corneal perforation. The Gram stain of the corneal scraping in the first case revealed Gram-positive cocci, while the second case showed encapsulated Gram-positive bacilli and encapsulated Grampositive cocci in chains. In both cases, repeated intrastromal injections of levofloxacin 1.5% in addition to increasing the frequency of topical levofloxacin 1.5% resulted in marked improvement in visual acuity and resolution of deep stromal infiltrates and hypopyon. Conclusion These cases highlighted the utility of intrastromal levofloxacin 1.5% ophthalmic solution in the management of recalcitrant Gram-positive bacterial keratitis.
Fluoroquinolones ; Levofloxacin

No abstract available.
Aged ; Humans ; Levofloxacin ; Plasma

Purpose: This study compared the safety outcomes of two intracameral fluoroquinolone antibiotics, moxifloxacin and levofloxacin, as prophylaxis treatment in eyes that underwent uncomplicated cataract surgery. Methods: This is a prospective, double-masked, randomized, interventional, single-center clinical trial. Eyes with visually-significant cataracts underwent phacoemulsification and received preservative-free intracameral 0.5% moxifloxacin [58 eyes (M group)] or 0.5% levofloxacin [56 eyes (L group)] at the end of the surgery as antibiotic prophylaxis. The following safety parameters were evaluated postoperatively at Day 1, Week 1 and Month 1: central retinal thickness (CRT), macular volume (MV), central corneal thickness (CCT), and endothelial cell density (ECD). In-between group comparison was made at each of the 4 study visits using Student’s t-test. Results: Both M and L groups had similar baseline characteristics. There were no significant differences in CRT, MV, CCT and ECD between the 2 groups at each time point in the study. There were no significant differences in the mean changes in CRT, MV, CCT and ECD from baseline to final visit between the 2 groups. No study-related adverse events were observed during the study period. Conclusion Intracameral application of preservative-free 0.5% moxifloxacin and 0.5% levofloxacin appear to have similar safety outcomes when used as antibacterial prophylaxis among eyes undergoing cataract surgery. Based on the results, both fluoroquinolone agents are potentially suitable options for endophthalmitis chemoprophylaxis.
Levofloxacin ; Moxifloxacin ; Fluoroquinolones

BACKGROUND/AIMS: For the investigation of the efficacy and safety of intravenous levofloxacin, The clinical study was carrried out in 30 patients with abdominal operation, especially in hepatobiliary and pancreatic division. METHODS: Randomly chosen patients received intravenous levofloxacin (250mg bid) for only 7 days. Clinical and microbiological evaluation were conducted on the day of starting and finishing levofloxacin treatmeat except for the case of combined use of antibiotics. RESULTS: The most commonly isolated organism was staphylococcus aureus(33%, 3/9). The overall bacteriologic eradication rate was 67%, (6/9) with clinical success rate was 96%(29/30), There were no significant dverse effects to stop the administration of the drug. CONCLUSION: These results suggest that intravenous levofloxacin is effective and safe antibiotics in the fields management of abdominal operation especially in hepatobiliary and pancreas surgery.
Anti-Bacterial Agents ; Humans ; Levofloxacin* ; Pancreas ; Staphylococcus

PURPOSE: Antibiotic is widely used in the treatment of chronic prostatitis. In this study, we evaluated the clinical efficacy and safety of levofloxacin (Cravit(R)) in the treatment of patients with chronic prostatitis. MATERIALS AND METHODS: Between March 2001 and February 2003, 64 patients with chronic bacterial (NIH-category II) and nonbacterial inflammatory prostatitis (NIH-category IIIa) were enrolled in this study. Daily 400 mg of levofloxacin was administered orally for 4-18 weeks. To determine the efficacy of levofloxacin, patients were assessed with the NIH-CPSI and examined of expressed prostatic secretion (EPS) at 3 months follow-up period. RESULTS: The CPSI of 16 patients stratified into NIH-category II was 24.9+/-4.7 before and 14.1+/-6.5 after the treatment. For 48 patients stratified into NIH-category IIIa, the CPSI value before and after the treatment was 23.9+/-4.4 and 13.2+/-5.7, respectively. 40 patients (62.5%) showed mild to moderate improvement in NIH-CPSI, and 23 patients (35.9%) showed improvement in the laboratory profile according to the count of leukocytes (WBC <10/HPF) in EPS. Adverse reaction was noted in 1 patient during the treatment. Conclusions:This study shows that levofloxacin may be a safe and effective agent in treating either chronic bacterial prostatitis or chronic nonbacterial inflammatory prostatitis with few adverse reactions.
Follow-Up Studies ; Humans ; Leukocytes ; Levofloxacin* ; Prostatitis*

PURPOSE: Antibiotic is widely used in the treatment of chronic prostatitis. In this study, we evaluated the clinical efficacy and safety of levofloxacin (Cravit(R)) in the treatment of patients with chronic prostatitis. MATERIALS AND METHODS: Between March 2001 and February 2003, 64 patients with chronic bacterial (NIH-category II) and nonbacterial inflammatory prostatitis (NIH-category IIIa) were enrolled in this study. Daily 400 mg of levofloxacin was administered orally for 4-18 weeks. To determine the efficacy of levofloxacin, patients were assessed with the NIH-CPSI and examined of expressed prostatic secretion (EPS) at 3 months follow-up period. RESULTS: The CPSI of 16 patients stratified into NIH-category II was 24.9+/-4.7 before and 14.1+/-6.5 after the treatment. For 48 patients stratified into NIH-category IIIa, the CPSI value before and after the treatment was 23.9+/-4.4 and 13.2+/-5.7, respectively. 40 patients (62.5%) showed mild to moderate improvement in NIH-CPSI, and 23 patients (35.9%) showed improvement in the laboratory profile according to the count of leukocytes (WBC <10/HPF) in EPS. Adverse reaction was noted in 1 patient during the treatment. Conclusions:This study shows that levofloxacin may be a safe and effective agent in treating either chronic bacterial prostatitis or chronic nonbacterial inflammatory prostatitis with few adverse reactions.
Follow-Up Studies ; Humans ; Leukocytes ; Levofloxacin* ; Prostatitis*

Green nail syndrome is characterized by greenish discoloration of the nail. It is caused by Pseudomas aeruginosa which is an aerobic gram-negative rod found in moist environment. The most common predisposing factors are frequent exposure to water and trauma history. Herein, we report two cases of green nail syndrome who developed greenish discoloration of finger nails, which were treated by systemic levofloxacin and gentian violet application.
Causality ; Fingers ; Gentian Violet ; Levofloxacin ; Pseudomonas aeruginosa ; Water

The drug eruptions caused by quinolones are rarely reported. The patient took norfloxacin for several days prior to admission and was admitted due to systemic erythematous maculopapular eruptions. For the treatment of urinary tract infection, he was treated with pefloxacin via intravenous route, and then the symptom of drug eruption became aggravated. After termination of treatment, the symptom reduced. The causative agent was identified by intradermal test and confirmed by accidental rechallenge with levofloxacin which is an another quinolone. We report herein the case of drug eruption caused by several quinolones which was confirmed by intradermal test and incidental administration of the drug.
Drug Eruptions* ; Humans ; Intradermal Tests ; Levofloxacin ; Norfloxacin ; Pefloxacin ; Quinolones* ; Urinary Tract Infections

BACKGROUND/AIMS: This study evaluated the eradication rate of levofloxacin-containing rescue therapy by treatment duration in patients in whom previous first- and second-line treatment failed. METHODS: Fifty-five patients with persistent Helicobacter pylori infection after first-line therapy and second-line therapy were studied in a single referral academic center. We compared the eradication rates by the treatment duration of third-line therapy. RESULTS: Of 55 patients, 12 (21.8%) received rescue therapy for seven days, 24 (43.6%) received rescue therapy for 10 days, and 19 (34.5%) received rescue therapy for 14 days. The eradication rates of therapy with levofloxacin were 65.5% in the 55 enrolled patients and 73.5% in the 49 patients who underwent follow-up testing. In cases where follow-up testing was performed, the eradication rate of 7-day therapy was 58.3%, of 10-day 68.2%, and of 14-day therapy 93.3%. Eradication rate of 14-day therapy was higher than 7-day (p=0.06) and 10-day (p=0.108), but chance could not be ruled out in the difference among groups. CONCLUSIONS: This study showed somewhat increasing of H. pylori eradication rate by extending the duration of levofloxacin-containing rescue therapy to 14 days.
Follow-Up Studies ; Helicobacter pylori* ; Helicobacter* ; Humans ; Levofloxacin* ; Referral and Consultation ; Treatment Failure*

In solid tumor, there is a hypoxic region where oxygen supply is insufficient. In this study, we found that one of the quinolone antibiotics, levofloxacin, made a human ovarian cancer cells, SK-OV-3, resistant to hypoxia, even in the presence of a platinum-based anti-cancer therapeutic, carboplatin; when the cells (2 X 10(5) cells/12 well multi culture dish) were grown in no glucose medium (0 g/l) under hypoxia (1% O2), all the cells became dead after 24 hours of culture in the absence of levofloxacin and carboplatin, whereas the cells still survived, at least, until 36 hours of culture in the presence of levofloxacin (10-100 microgram/ml) alone or in combination with carboplatin. The results might have some implications in treating solid tumor; if cancer patients should be treated for infection with antibiotics, quinolone antibiotics can aggravate tumor by making cancer cells more resistant to hypoxia. This is also true even when a patient is treated with carboplatin. Therefore, the results strongly suggest that we should be careful in choosing antibiotics when they are used for cancer patients. In this regard, our work could be a new guideline in choosing antibiotics when antibiotics are applied for treating cancer patients.
Anoxia ; Anti-Bacterial Agents ; Carboplatin* ; Cell Survival ; Glucose ; Humans ; Levofloxacin* ; Ovarian Neoplasms* ; Oxygen